Biocryst Pharmaceuticals buy JPMorgan Chase & Co.
Start price
06.05.25
/
50%
€9.37
Target price
06.05.26
€11.51
Performance (%)
-30.04%
Price
10:40
€6.55
Summary
This prediction is currently active. The BUY prediction by JPMorgan_Chase___Co_ for Biocryst Pharmaceuticals is performing very badly with a performance of -30.04%. This prediction currently runs until 06.05.26. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Biocryst Pharmaceuticals | 2.726% | 2.726% |
| iShares Core DAX® | 0.794% | 2.841% |
| iShares Nasdaq 100 | 0.016% | -0.939% |
| iShares Nikkei 225® | 0.309% | -0.648% |
| iShares S&P 500 | 0.181% | -0.442% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its price target raised by analysts at JPMorgan Chase & Co. from $10.00 to $13.00. They now have an "overweight" rating on the stock.
Ratings data for BCRX provided by MarketBeat
Stopped prediction by JPMorgan_Chase___Co_ for Biocryst Pharmaceuticals
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€4.86
20.11.23
20.11.23
€9.15
20.11.24
20.11.24
44.15%
21.11.24
21.11.24

